Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cenicriviroc/tropifexor - Allergan/Novartis

Next Previous
Drug Profile

Cenicriviroc/tropifexor - Allergan/Novartis

Alternative Names: CVC/LJN452; LJC-242; Tropifexor/Cenicriviroc - Novartis/Allergan

Latest Information Update: 24 Jan 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Developer AbbVie; Novartis
  • Class Amides; Anti-inflammatories; Antifibrotics; Antineoplastics; Antiretrovirals; Benzothiazoles; Hepatoprotectants; Imidazoles; Oxazoles; Small molecules
  • Mechanism of Action CCR2 receptor antagonists; CCR5 receptor antagonists; Farnesoid X-activated receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-alcoholic steatohepatitis

Most Recent Events

  • 24 Jan 2023 Cenicriviroc/tropifexor is still in phase II trial in Non-alcoholic steatohepatitis in USA, Belgium, Czech Republic, France, Germany, Italy, Latvia, Portugal, Singapore, Spain, the UK, Argentina, Canada, Egypt, India, Israel, Russia and Turkey (PO)
  • 06 May 2021 Novartis announces intention to submit regulatory applications for Non-alcoholic steatohepatitis in or after 2025
  • 13 Oct 2020 Novartis and AbbVie complete the TANDEM phase II trial in Non-alcoholic steatohepatitis in USA, Belgium, Czech Republic, France, Germany, Italy, Latvia, Portugal, Singapore, Spain, the UK, Argentina, Canada, Egypt, India, Israel, Russia and Turkey (PO) (NCT03517540) (EudraCT2017-004208-24)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top